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Background: Pulmonary exposure to nanoparticles (NPs) may affect, in addition to pulmonary toxicity, the
cardiovascular system such as procoagulant effects, vascular dysfunction and progression of atherosclerosis.
However, only few studies have investigated hemostatic effects after pulmonary exposure.
Methods: We used Bmal1 (brain and muscle ARNT-like protein-1) knockout (Bmal1−/−) mice which have a disturbed
circadian rhythm and procoagulant phenotype, to study the pulmonary and hemostatic toxicity of multi-walled
carbon nanotubes (MWCNTs) and zinc oxide (ZnO) NPs after subacute pulmonary exposure. Bmal1−/− and wild-type
(Bmal1+/+) mice were exposed via oropharyngeal aspiration, once a week, during 5 consecutive weeks, to a cumulative
dose of 32 or 128 μg MWCNTs or 32 or 64 μg ZnO NPs.
Results: MWCNTs caused a pronounced inflammatory response in the lung with increased cell counts in the
broncho-alveolar lavage and increased secretion of interleukin-1β and cytokine-induced neutrophil chemo-attractant
(KC), oxidative stress (increased ratio of oxidized versus reduced glutathione and decreased total glutathione) as well as
anemic and procoagulant effects as evidenced by a decreased prothrombin time with increased fibrinogen
concentrations and coagulation factor (F)VII. In contrast, the ZnO NPs seemed to suppress the inflammatory (decreased
neutrophils in Bmal1−/− mice) and oxidative response (increased total glutathione in Bmal1−/− mice), but were also
procoagulant with a significant increase of FVIII. The procoagulant effects, as well as the significant correlations between
the pulmonary endpoints (inflammation and oxidative stress) and hemostasis parameters were more pronounced in
Bmal1−/− mice than in Bmal1+/+ mice.
Conclusions: The Bmal1−/− mouse is a sensitive animal model to study the procoagulant effects of engineered NPs.
The MWCNTs and ZnO NPs showed different pulmonary toxicity but both NPs induced procoagulant effects,
suggesting different mechanisms of affecting hemostasis. However, the correlation analysis suggests a causal
association between the observed pulmonary and procoagulant effects.
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The rapid developments in nanotechnologies have in-
creased the production of nanoparticles (NPs). These
engineered NPs are, due to their unique physico-chemical
properties, currently incorporated in thousands of prod-
ucts in a broad range of industries. This leads to an
increased risk of exposure in occupational and environ-
mental settings [1]. Obviously, the lungs are an important
target for toxicity studies since it is the main exposure
route and site of particle deposition. However, the effects
are probably not limited to the respiratory tract, since en-
vironmental ultrafine particles (UFP) can cause cardiovas-
cular toxicity/morbidity and lately, similar observations
have been made for NPs [2].
Epidemiological studies showed associations between
environmental particulate matter exposure and athero-
sclerosis and an increased risk for myocardial infarction
[3,4]. People living near (<245 meters) a major traffic
road have an increased risk for deep vein thrombosis [5].
These effects are even more pronounced in human pop-
ulations with underlying cardiovascular disease or risk
factors (diabetes mellitus, hypertension, heart failure)
[6-9]. Experimental animal models established that pul-
monary titanium dioxide (TiO2) NP exposure signifi-
cantly impairs endothelium-dependent vasoreactivity in
rat coronary arterioles [10]. Intratracheal administration
of aminated polystyrene NPs (5 mg/kg) significantly in-
creased thrombus formation in the femoral vein in a
hamster model [11]. Subchronic exposure to low doses
of single-walled carbon nanotubes (SWCNT) and multi-
walled carbon nanotubes (MWCNT) resulted in acceler-
ated plaque formation in apo lipoprotein E knockout
(ApoE−/−) mice [12,13].
Bmal1 (brain and muscle ARNT-like protein) is a basic
helix-loop-helix-PAS domain-containing transcription
factor and is, together with another member of this fam-
ily, CLOCK, the key component of the molecular oscilla-
tor that generates circadian rhythms [14,15]. The central
component of the circadian clock is located in the hypo-
thalamic suprachiasmatic nucleus (SCN), near the optic
chiasm. Environmental information (light/dark) received
via the retina synchronizes the internal clock, and the
SCN, in its turn, synchronizes the activity of peripheral
oscillators present in every cell of an organism. These
peripheral oscillators generate rhythms in gene expression,
metabolism, and hormone secretion which ultimately re-
sult in rhythmic changes in physiology and behavior, pre-
sumably as an adaptation to the daily changes in the
environment [16]. Mice with a dysfunctional circadian
clock lacking the Bmal1 gene have been shown to have a
prothrombotic state due to increased platelet aggregation
and adhesion, compared to Bmal1+/+ mice [17]. They
display vascular disease with endothelial dysfunction
due to hyperactivated endothelial cells and an impairedendothelium-dependent vasorelaxant response [18,19].
Bmal1−/−mice have an average lifespan of 37.0 ± 12.1 weeks
and spontaneous deaths start at the age of 26 weeks. Also,
some phenotypical changes associated with premature
ageing are present such as the development of cataracts
(starting at the age of only 18 weeks), decreased adipose
and muscle tissue mass compared to Bmal1+/+ mice and
reduced hair growth [20].
These observed phenotypes are caused by the deregu-
lation of reactive oxygen species (ROS). Bmal1 directly
regulated ROS and its deficiency leads to an excessive
ROS production, leading to chronic oxidative stress [20].
The role of oxidative stress in the early onset of ageing
in Bmal1−/− mice has been proven by the increased life
span due to the dietary supplementation of the antioxi-
dant N-acetyl cysteine (NAC). Also the development of
cataracts was attenuated, but growth retardation, re-
duced hair regrowth, sarcopenia and joint ossification
were not affected by NAC administration suggesting the
involvement or other mechanisms besides oxidative
stress for the increased ageing [21]. Several clinical con-
ditions have been linked to chronic oxidative stress, in-
cluding cardiovascular disease. An excessive stimulation
of NAD(P)H oxidase activity by cytokines or other
agents drives the increased ROS levels and are often asso-
ciated with pathological changes indicative of a deregula-
tion of signaling cascades and/or gene expression [22].
The Bmal1−/− mouse has phenotypic characteristics of
people with cardiovascular disease which are driven by
oxidative stress and it is therefore believed to be a good
model to study extra-pulmonary toxicity such as effects
on coagulation and the vasculature, after pulmonary ex-
posure to NPs. Additional to the role of the Bmal1 gene in
the cardiovascular system, the Bmal1−/− mouse model pre-
viously has been used for research regarding osteogenesis,
myogenesis, insulin resistance and obesity [23-25].
In order to assess whether Bmal1−/− mice are more
prone to the adverse effects of pulmonary administered
NPs, we subacutely exposed Bmal1−/− and Bmal1+/+ mice
to MWCNT or ZnO NPs, via oropharyngeal aspiration.
24 hours or 8 weeks after the last administration, we
assessed pulmonary inflammation and oxidative stress to-
gether with effects on blood cell counts, coagulation status
and the early onset of vascular inflammation (macrophage
influx).
Results
Broncho-alveolar lavage
The total amount of cells in the broncho-alveolar lavage
(BAL) fluid, and the fraction of macrophages, neutrophil,
eosinophils and lymphocytes herein were calculated for
each mouse. In general, the total BAL cell numbers
more than doubled (p = 0.001) after administration of
MWCNT without difference between the two dose
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total number of BAL cells was lower after the high
MWCNT dose compared to the low MWCNT dose
(confirmed by the concentration x genotype interaction
of principal component 1; p = 0.015). The number of
BAL cells, after MWCNT treatment was significantly
higher after 24 hours (T1) compared to 8 weeks later
(T2) (p = 0.002). The same trends were observed for the
ZnO NPs, however, the differences were less pro-
nounced and not significant (Figure 1E). The macro-
phages made up the largest fraction of BAL cells andFigure 1 Pulmonary inflammatory endpoints measured in Bmal1+/+ a
exposure to multi-walled carbon nanotubes or zinc oxide nanoparticl
concentration (C, G) and pulmonary KC concentration (D, H) were measur
depict measurements at T2. Significant differences between the experimen
(a, b and c). The effects after NP administration is indicated with letters dep
of this group compared to the control of the same time point, within the s
to the same experimental group of T1. ΔΔp < 0.01 compared to the same
the figure, the time effects (Δ) are observed in all experimental groups.followed the same pattern as the total amount of BAL
cells. For the MWCNTs, the neutrophils also followed
the same pattern as the total BAL cell count (Figure 1B).
However, the ZnO NPs caused, at T1, a neutrophil in-
crease in Bmal1+/+ mice, but a neutrophil decrease in
Bmal1−/− mice (concentration x genotype interaction:
p = 0.04; Figure 1F). Also, the highest numbers of neu-
trophils were found at T1 as compared to T2 (p = 0.004
for MWCNT and p = 0.02 for ZnO NPs) and these were
generally higher in the Bmal1−/− mice than in Bmal1+/+
mice (p = 0.009 for MWCNT) (data not shown).nd Bmal1−/− mice, 24 hours (T1) and 8 weeks (T2) after the last
es. Total BAL cells (A, E), BAL neutrophils (B, F), pulmonary IL-1β
ed in each mouse. White bars depict measurements at T1, grey bars
tal groups due to the NP administration are depicted by letters
icted above the groups. A different letter indicates a significant effect
ame genotype. Time-effects are indicated by Δ. Δp < 0.05 compared
experimental group of T1. When a symbol is placed in the middle of
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count the cellular influx in the lung showed a positively
correlation with all 5 variables (total BAL cells and the
number of each cell type) and accounted for 55% and 52%
of the total variability for MWCNT (p = 0.0005) and ZnO
NPs (p = 0.008), respectively. Results using PCA were very
similar to those of the total cell counts (data not shown).
The BAL macrophages show evidence of internalized
MWCNTs up to T2 for both concentrations and both
genotype (Figure 2). Data are only shown for the Bmal1−/−
mice. On the other hand, the ZnO NPs were not visible
in these cells. A summary of the data can be found in
Table 1.Cytokines in lung homogenates
From the panel of pro-inflammatory cytokines mea-
sured, only the levels of IL-1β and KC were above the
lower limit of detection. Administration of MWCNTs
dose-dependently increased IL-1β (p < 0.001) and KC
(p < 0.001) secretion in the lungs (Figures 1C and 1D).
At T2 evidence of an inflammatory response was still
present (increased IL-1β levels). Administration of the
ZnO NPs did not have significant effects on the cytokine
secretion. At T2, the KC levels in the exposed groups were
decreased in the Bmal1+/+ mice, but increased in the
Bmal1−/− mice (three-way interaction, p = 0.023). A sum-
mary of the data can be found in Table 1.Figure 2 BAL cells of Bmal1−/− mice exposed to MWCNTs and ZnO NP
CNT-laden macrophages in the BAL 8 weeks after the last administration (T
show – at this magnification - any inclusions of particulate material.Pulmonary oxidative stress
Exposure to MWCNTs decreased the total glutathione
concentrations (T1: 57.1% of the control, T2: 78.5% for
Bmal1+/+ mice; T1: 68.2%, T2: 74.7% for Bmal1−/− mice;
p = 0.0001) with levels being higher for the Bmal1+/+
mice than the Bmal1−/− mice (p = 0.034) (Figure 3A).
The GSSG/GSH ratio increased after MWCNT adminis-
tration (T1: 172.8%, T2: 211.4% for Bmal1+/+ mice, T1:
133.1%, T2: 90% for Bmal1−/− mice; p = 0.005) and was
higher at T1 (p = 0.003) than at T2 (Figure 3B). The
ZnO NPs increased the total amount of glutathione in
the lungs (T1: 101.5%, T2: 127.6% for Bmal1+/+ mice;
T1: 242.8%, T2: 148.7% for Bmal1−/− mice; p = 0.0002),
with values being highest at T1 compared to T2, again
only in the Bmal1−/− mice (time x genotype interaction,
p = 0.028) (Figure 3C). The GSSG/GSH ratio signifi-
cantly decreased (Figure 3D) after ZnO NP exposure
(T1: 7.1%, T2: 52.9% for Bmal1+/+ mice, T1: 3.3%, T2:
27.8% for Bmal1−/− mice; p < 0.0001).Blood cell counts
The total counts of white blood cells (WBC) significantly
differed between the genotypes, with the Bmal1−/− mice
having significantly higher WBC values compared to the
Bmal1+/+ mice (p = 0.002 for MWCNTs and p < 0.0001
for ZnO NPs), but no effect of NP administration on the
WBC levels could be detected (data not shown). Thes. Both groups receiving the low and high dose of MWCNT showed
2) whereas the BAL cells of the mice exposed to the ZnO NPs did not
Table 1 Summary of the nanoparticle-induced, genotype
and time effects
MWCNT ZnO Genotype
effect
Time effect
Pulmonary toxicity:
BAL cells ↑↑ ≈ ≈ ↓ (only WT)
Lung cytokines ↑↑ ↓ ≈ ↓
Oxidative stress ↑↑ ↓ ↓ ↓
Extra-pulmonary toxicity:
Inflammatory blood cells ≈ ≈ ↑ ≈
Red blood cells - platelets ↓ ≈ ↑ ↑
Coagulation ↑↑ ↑ ↑ ≈↑
Vascular inflammation ≈ ≈ ≈ ≈
The genotype effects represent the effects induced by both NPs in the Bmal1 −/−
mice as compared to those of the Bmal1 +/+ mice; the time effects represent the
effects induced by both NPs at T2 as compared to T1, without a distinction
between both genotypes. ↑↑ represents a significant increase (p< 0.01) compared
to its proper respectively control group; ↑ increase (p< 0.05); ↓↓ decrease
(p< 0.01); ↓ decrease (p< 0.05); ≈ no significant change.
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the same pattern (data not shown).
Overall, MWCNT decreased the number of red blood
cells (RBC) in the blood (73.2% of the control), only in
the Bmal1+/+ mice (Figure 4A). The numbers were
higher at T2 than at T1 and the Bmal1−/− mice had
higher values than the Bmal1+/+ mice. Effects of dose,
genotype and timepoint were not additive, as indicated
by a three-way interaction effect (p = 0.035). ZnO NPsFigure 3 Total glutathione and ratio of oxidized versus reduced gluta
24 hours (T1) and 8 weeks (T2) after the last exposure to MWCNTs or
measured in lung homogenates of each mouse. White bars depict measurem
indicates a significant effect of this group compared to the control of the sam
same experimental group of T1. ΔΔp < 0.01 compared to the same experime
Bmal1+/+ and Bmal1−/− mice. When a symbol is placed in the middle of the fi
experimental groups.did not affect the RBC levels (Figure 4G), however the
observations regarding time (p = 0.0002) and genotype
(p = 0.029) were similar.
The Mean Corpuscular Volume (MCV) was however
not affected by the MWCNT exposure, meaning that the
hemolytic response was not accompanied by a de novo
RBC production. The MCV was lowest in the Bmal1−/−
animals at T2 (time x genotype interaction: p = 0.017 for
MWCNTs and p = 0.044 for ZNO NPs).
The number of platelets was not significantly affected
by the administration of either NP (Figure 4B and 4H),
however the mice at T2 had significantly higher platelet
levels than the mice at T1 (p < 0.0001 for MWCNT and
p = 0.0008 for ZnO) and the Bmal1−/− mice also had
more platelets (T1: 149.3% of the control, T2: 143.6%)
than the Bmal1+/+ mice (p < 0.0001 for both NPs). The
Mean Platelet Volume (MPV) correlated to the number
of platelets where this parameter was higher at T1 than
at T2 and also higher in the Bmal1+/+ mice than the
Bmal1−/− mice. A summary of the data can be found in
Table 1.
Hemostasis parameters
MWCNT administration decreased the PT (T1: 91.4% of
the control, T2: 89.9% for Bmal1+/+ mice, T1: 95.3%, T2:
91.3% for Bmal1−/− mice; p = 0.021), without a difference
between both doses (Figure 4C). Also, the Bmal1−/− mice
had lower values than the Bmal1+/+ mice (T1: 82.5%,
T2: 88.2%; for both NPs p < 0.0001). The fibrinogenthione measured in lungs of Bmal1+/+ and Bmal1−/− mice,
ZnO NPs. Total glutathione (A, C) and the GSSG/GSH ratio (B, D) were
ents at T1, grey bars depict measurements at T2. A different letter
e time point, within the same genotype. Δp < 0.05 compared to the
ntal group of T1. Genotype-effects are indicated by Φ. Φp < 0.05 between
gure, the time (Δ) and genotype-effects (Φ) are observed in all
Figure 4 (See legend on next page.)
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Figure 4 Extra-pulmonary endpoints measured in Bmal1+/+ and Bmal1−/− mice, 24 hours (T1) and 8 weeks (T2) after the last exposure
to MWCNTs or ZnO NPs. Total amount of red blood cells, (RBC) (A, G), total amount of platelets (B, H) measured in diluted whole blood of all
mice. PT (C, I), fibrinogen concentrations (D, J), coagulation factor VII (E, K) and VIII (F, L) measured in plasma of each mouse. White bars depict
measurements at T1, grey bars depict measurements at T2. Δp < 0.05 compared to the same experimental group of T1. ΔΔp < 0.01 compared to
the same experimental group of T1. ΔΔΔp < 0.001 compared to the same experimental group of T1. Φp < 0.05 between Bmal1+/+ and Bmal1−/−
mice. ΦΦp < 0.01 between Bmal1+/+ and Bmal1−/− mice. ΦΦΦp < 0.001 between Bmal1+/+ and Bmal1−/− mice. When a symbol is placed in the
middle of the figure, the time (Δ) and genotype-effects (Φ) are observed in all experimental groups.
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exposed to the MWCNTs (125.5% of the control p = 0.036),
but not to the ZnO NPs (Figure 4D). Overall, the Bmal1−/−
mice had higher fibrinogen concentrations than the
Bmal1+/+ mice (153.1% of the control, p < 0.0001) and
after MWCNT exposure the level at T1 was higher than
at T2 (time x genotype interaction: p = 0.029) (Figures 4D
and 4J).
Both NPs did not have an effect on the concentrations
of coagulation factor FVII, however the Bmal1−/− mice
had higher values of this coagulation factor than the
Bmal1+/+ mice (117.8%; p < 0.0001 for the MWCNTs and
p = 0.009 for ZnO NPs). The coagulation factor FVIII was
not affected by MWCNT administration. The ZnO NPs
increased FVIII (T1: 123.9%, T2: 124.4% for Bmal1+/+
mice, T1: 120.3%, T2: 128.9% for Bmal1−/− mice; p =
0.001) in both genotypes and at both time points.
In a PCA involving PT, fibrinogen, FVII and FVIII, the
first PC was positively correlated with the fibrinogen
concentration and coagulation factors FVII and FVIII
and negatively correlated with PT, so these parameters
are a good measure for coagulation. For the MWCNTs
the first PC accounted for 60% of the variability and 55%
for the ZnO NPs. For MWCNT administration, this first
PC showed a significant dose effect (higher values for
both doses than in the control group, p = 0.006), higher
values at T1 than T2 (p = 0.03) and higher values in the
Bmal1−/− mice than in the WT (p < 0.001), which is in
line with the results for PT and fibrinogen separately.
For ZnO NP administration, there was only a difference
for genotype (higher values in Bmal1−/− mice, p = <0.001),
which again confirmed the results for PT, fibrinogen and
FVII. A summary of the data can be found in Table 1.
Aorta histology
The proximal section of the aorta (aortic arch) was dis-
sected and vertical sections were made, perpendicular to
the surface of the tissue. The sections were stained for F4/
80, a macrophage antigen, in order to assess early vascular
inflammation. There were no significant differences in F4/
80 staining between the different groups (data not shown).
Correlations
When considering all pulmonary endpoints measured,
we could observe a strong positive correlation betweenthe BAL neutrophils and both cytokine concentrations:
IL-1β (Pearson correlation coefficient (PCC): 0.696, p =
0.0007) and KC (PCC: 0.671, P = 0.0012), in the Bmal1+/+
mice exposed to ZnO NPs. These correlations were not
present in the Bmal1−/− mice, however, the IL-1β concen-
trations and total glutathione (PCC: 0.512, p = 0.0297)
were correlated. For the MWCNT-exposed mice, there
were only correlations between both cytokines in both ge-
notypes in the Bmal1+/+ mice and in the Bmal1−/− mice,
the BAL neutrophils were correlated with both cytokines:
IL-1β (PCC: 0.633, p = 0.0201) and KC (PCC: 0.665, p =
0.01232) (data not shown).
When considering all toxicological endpoints measured,
we could also observe correlations between pulmonary in-
flammation, oxidative stress and the hemostasis parame-
ters. In the Bmal1+/+ mice exposed to MWCNTs, the BAL
neutrophils were positively correlated with fibrinogen con-
centrations in the blood (PCC: 0.644, p = 0.0095) and in
the Bmal1−/− mice, the IL-1β concentrations were posi-
tively correlated with fibrinogen concentrations (PCC:
0.620, p = 0.0179). In the Bmal1+/+ mice exposed to ZnO
NPs, the total BAL cells were positively correlated with fi-
brinogen (PCC: 0.572, p = 0.0105).
An additional analysis was performed where all mice
of the same genotype were pooled, independent of the
nanomaterial they were exposed to (see Table 2). In the
Bmal1+/+ mice, a positive correlation was found between
the BAL neutrophils and fibrinogen concentrations (PCC:
0.584, p = 0.0003) and negative correlations were found
between the PT and BAL neutrophils (PCC: −0.380, p =
0.0265), IL-1β concentration (PCC: −0.483, p = 0.0053)
and KC concentrations (PCC: −0.426, p = 0.015). In the
Bmal1−/− mice, the fibrinogen concentrations were corre-
lated with the IL-1β concentrations (PCC: 0.656, p < 0.0001),
KC concentrations (PCC: 0.538, p = 0.0018) and GSSG/GSH
ratio (PCC: 0.412, p = 0.019). The PT is negatively corre-
lated with KC concentrations (PCC: −0.413, p = 0.0208).
Discussion
In this study we assessed the pulmonary and extra-
pulmonary toxicity of MWCNTs and ZnO NPs after re-
peated pulmonary administrations. To our knowledge,
this is the first study where Bmal1−/− mice are used to
study NP pulmonary toxicity and the effect on coagula-
tion after pulmonary NP exposure.
Table 2 Pearson correlation coefficiants between the pulmonary and cardiovascular endpoints measured
BAL total BAL neutrophils IL1β KC Total glutathione GSSG/GSH ratio PT Fibrinogen
PCC: 0.464 PCC: 0.090 PCC: 0.095 PCC: −0.088 PCC: 0.120 PCC: −0.067 PCC: 0.112 BAL total
p = 0.0044 p = 0.6110 p = 0.5914 p = 0.5980 p = 0.4739 p = 0.6985 p = 0.5167
PCC: 0.514 PCC: 0.408 PCC: 0.395 PCC: −0.056 PCC: 0.213 PCC: −0.172 PCC: 0.229
p = 0.0011 p = 0.0228 p = 0.028 p = 0.7607 p = 0.2427 p = 0.3153 p = 0.1789
PCC: 0.224 PCC: 0.357 PCC: −0.175 PCC: 0.138 PCC: −0.380 PCC: 0.584 BAL neutrophils
P = 0.2103 p = 0.0417 p = 0.3073 p = 0.4222 p = 0.0265 p = 0.0003
PCC: 0.702 PCC: 0.675 PCC: −0.243 PCC: 0.320 PCC: −0.299 PCC: 0.319
p < 0.0001 p < 0.0001 p = 0.1800 p = 0.0739 p = 0.0765 p = 0.0582
PCC: 0.652 PCC: −0.457 PCC: 0.541 PCC: −0.483 PCC: −0.067 IL1β
p < 0.0001 p = 0.0066 p = 0.001 p = 0.0053 p = 0.7155
PCC: 0.768 PCC: −0.486 PCC: 0.457 PCC: −0.229 PCC: −0.656
p < 0.0001 p = 0.0065 p = 0.0111 p = 0.2143 p < 0.0001
PCC: −0.121 PCC: 0.082 PCC: −0.426 PCC: −0.128 KC
p = 0.4948 p = 0.6429 p = 0.015 p = 0.4845
PCC: −0.367 PCC: 0.319 PCC: −0.413 PCC: −0.538
p = 0.0458 p = 0.0857 p = 0.0208 p = 0.0018
PCC: −0.715 PCC: 0.233 PCC: −0.268 Total glutathione
p < 0.0001 p = 0.1707 p = 0.1145
PCC: −0.518 PCC: 0.148 PCC: −0.311
p = 0.002 p = 0.4179 p = 0.0834
PCC: −0.121 PCC: 0.181 GSSG/GSH ratio
p = 0.4821 p = 0.291
PCC: −0.163 PCC: 0.412
p = 0.3717 p = 0.019
PCC: −0.446 PT
p = 0.0064
PCC: −0.727
p < 0.0001
Fibrinogen
Pearson correlation coefficients (PCC) with concomitant p-values are presented for the measured endpoints. A comparison was made between the NP-exposed mice
and the controls where the results of both NPs were pooled. The plain values represent the results from the Bmal1+/+ mice and the bold values represent the results
from the Bmal1−/− mice. The values in italic are non-significant correlations where a p-value of 0.05 was considered to be significant. No correlations were found for RBC
and platelet counts, FVII and FVIII.
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Considering the pulmonary endpoints measured, the
two NPs evoked different responses; MWCNTs induced
a pronounced pulmonary inflammatory response with
increased BAL cells, secretion of IL-1β and KC and a
clear induction of oxidative stress; in contrast, the ZnO
NPs induced a different pattern of effects in the lungs, i.e.
a limited cellular influx in the lung and an increased total
glutathione content. The findings after MWCNTs admin-
istration are not surprising; it was shown in earlier studies
that carbon nanotubes (CNTs) cause pulmonary inflam-
mation (with granuloma formation) which can persist up
to 1 month after the administration [26,27]. Here, thenumber of BAL cells, together with the measured cyto-
kines, decreased over the 8 weeks after the last administra-
tion, however they were still elevated compared to the
control. This is probably caused by the incomplete clear-
ance of MWCNT which was apparent from the presence
of MWCNT loaded (black) macrophages in the BAL at
T2 (see Figure 2). The BAL macrophages of ZnO NP-
exposed animals did not show internalized NPs, possibly
because these NPs are less electron dense than MWCNTs
and/or the ZnO NPs can solubilize within the time win-
dow of the experiment.
In acute inhalation studies, in general, ZnO NPs show a
transient acute pulmonary inflammatory response [28,29].
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a single acute exposure (inhalation of 0.86 mg/m3 during
5 hours), but after inhalation of ZnO NPs at the same dose
during 5 consecutive days no inflammation was found
[30]. This is comparable to observations in humans after
pulmonary exposure to high doses of zinc and/or zinc ox-
ides. A syndrome known as metal fume fever (MFF) is an
acute inflammatory response which resolves 1–4 days
after exposure [31]. However, there are some discrepancies
with regard to the dose of which MFF is triggered. Several
studies reported symptoms after exposure ranging from
77 mg zinc/m3 (15–30 minutes) to 600 mg zinc/m3 (10–
12 minutes), whereas concentrations slightly higher than
the permissible exposure limit (5 mg/m3) during several
hours did not elicit MFF-like symptoms [32].
The subacute exposure of ZnO NPs in this study only
led to a very mild (and non-significant) total BAL cell in-
crease 24 h after the last administration, which decreases
at T2. The differences with the aforementioned studies
are the method of exposure (inhalation vs. oropharyn-
geal aspiration) and therefore, the doses cannot easily be
compared. In the current study, we chose to administer
multiple times a low dose (6.4 or 12.8 μg/instillation)
thus avoiding local epithelial damage in the lung and
acute toxicity. This procedure might explain the lack of
a significant inflammatory response, as in the study by
Chen et al. [30]. Considering only the BAL neutrophils
in the Bmal1+/+ mice, our data are in accordance with
other reports, although a decrease in neutrophils was
observed in the Bmal1−/− mice, accompanied by a sig-
nificant decrease of pulmonary cytokines and a signifi-
cant increase in total glutathione.
Moreover, a zinc excess is known to suppress immunity.
In humans, plasma-zinc occurs in a concentration of only
12–16 μmol/L but a deficiency as well as an excess cause
decreased function of several immune cells [33,34]. Zinc
excess causes macrophage activation, directs the chemo-
tactic activity of neutrophils and suppression of NK cell
functions. Also, T cell functions are suppressed and B cells
undergo apoptosis [34]. We presume that our doses are at
the border of toxicity explaining the absence of pulmonary
inflammation and the suppression of cytokine release. We
also cannot distinguish between effects caused by dis-
solved or particulate Zn. Preliminary dissolution studies
showed a pronounced dissolution in water and a some-
what lower dissolution in medium [35]. The dispersion
medium (sterile water) used in this study contained 2 vol%
serum which can possibly reduce the dissolution (com-
pared to water) during the preparation of the samples.
Taking into account the large volume for dissolution of Zn
in a vivo system it can be assumed that the ZnO NPs
dosed will finally solubilize fully.
Possibly, the responsiveness of the immune system in
the Bmal1−/− mice differed from that of the Bmal1+/+mice. Bmal1 has anti-inflammatory effects since it reduced
Ccl2 transcription and attenuated Ly6Chi monocyte
numbers and inflammation at an inflamed site [36,37]. In-
flammatory diseases (asthma, rheumatoid arthritis, athero-
sclerosis) are known to have strong circadian components
with exacerbations at night or during the early morning.
Moreover, several experimental studies showed a worse
disease outcome or higher mortality when wild-type mice
were housed in constant darkness than at the normal
light/dark cycles [37]. So, given these results, one would
expect an increased inflammatory response in Bmal1−/−
mice, however, we found a similar vascular macrophage
influx in both genotypes for the MWCNTs. Moreover,
Hemmeryckx et al. showed an absence of vascular in-
flammatory response in the mesenteric blood vessels of
Bmal1−/− mice despite the high numbers of circulating
leukocytes, suggesting these cells are less reactive [19].
Nanoparticle-induced hemostasis effects
The pulmonary administration of the NPs caused hemo-
static toxicity, in addition to the observed pulmonary ef-
fects. The MWCNTs showed a remarkable anemic effect
with significantly decreased RBCs and non-significantly
decreased platelets at the cumulative dose of 128 μg. How-
ever, these observations were absent in the Bmal1−/− mice.
Most research regarding hemolysis has been performed
on human or animal whole blood with direct contact with
the RBCs [38,39]. However, one study has shown the
hemolytic effect of acid functionalized SWCNTs after
intratracheal instillation in Swiss mice [40]. The effect was
transient with RBC counts returning to semi-normal levels
after 72 hours. As an explanation for this anemic response,
the authors suggested the possibility of SWCNTs to rap-
idly diffuse through the thin alveolar membrane. However,
we doubt that the anemic response is a direct effect since
it has been shown that CNTs are cleared very poorly from
the lungs and thus only a very small portion of the admin-
istered dose might eventually reach the blood stream.
Elgrabli et al. observed the retention of 37% of the admin-
istered dose, 3 months after a single instillation of 100 μg
CNTs in a rat lung [41]. Muller et al. observed the reten-
tion of 81.2% of the administered dose, 60 days after the
instillation of 0.5 mg/rat [42].
A possible explanation for this acute anemic response
is the state of “anemia of inflammation” which is an im-
mune disorder that has been reported in numerous
diseases with an inflammatory component [43]. As an
example, in chronic obstructive pulmonary disease
(COPD) an incidence of anemia has been reported ran-
ging from 5 – 33%, with highest incidences during acute
exacerbations [44-46]. It is believed that inflammatory
cytokines interfere with normal erythropoiesis in a com-
plex process where the dysregulation in iron homeosta-
sis and erythropoietin production, impaired proliferation
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RBCs are involved [47]. Here, the observed anemic effect
is acute and resolves at T2, which coincides with the de-
creased pulmonary inflammation at T2.
The subacute administration of both NPs also caused
a procoagulant effect with the MWCNTs causing a sig-
nificantly shorter PT and increased fibrinogen concen-
trations while ZnO NPs exposure significantly increased
the amount of coagulation factor VIII. Local inflamma-
tion can induce an acute phase response which is a non-
specific systemic reaction with neurological, endocrine
and metabolic alterations [48]. As a consequence, several
plasma proteins are induced e.g. C-reactive protein, cy-
tokines and coagulation factors. Fibrinogen and FVIII
are both acute phase proteins, associated with cardiovas-
cular disease [49,50]. The hemostatic effects induced by
MWCNTs can be explained by this reaction; however,
the ZnO NPs did not cause an inflammatory response
suggesting that both NPs affect hemostasis by different
mechanisms. Possibly, other factors e.g. oxidized lipids
and proteins can be involved activating the acute phase
response and/or neurohumoral signaling, resulting in an
altered cardiovascular function. It is possible that none
of these mediators individually stimulate the extrapul-
monary responses but together orchestrate this response
[51]. Moreover, the Pearson’s correlations analysis indi-
cated a correlation between the fibrinogen concentra-
tions on the one hand and BAL neutrophils and IL-1β
concentrations in the lungs on the other hand, for the
MWCNT-exposed mice. This is suggestive for a causal
relation between the pulmonary inflammation with the
observed prothrombotic effects.
The hemostatic effects were more pronounced in the
Bmal1−/− mice, but also present in the Bmal1+/+ mice.
Previous studies reported a prothrombotic effect after
acute pulmonary administration of NPs. Jun et al. ob-
served enhanced venous thrombus formation and platelet
aggregation after the intratracheal instillation of 5–10 mg/
kg bw silver NPs in rats [52]. Starting from a concen-
tration of 50 μg diesel exhaust particles (DEPs), Nemmar
et al. observed acute increased thrombosis formation in
the right femoral vein and artery in hamsters [53]. On the
contrary, Zhu et al. reported an increased PT and aPTT
compared to the control, 30 days after intratracheal instil-
lation of 0.8 mg/kg bw ferric oxide NPs in rats [54].
Yoshida et al. also reported an increased aPTT and mar-
ginally increased PT after the intranasal administration of
0.5 mg 30 nm and 70 nm SiO2 NPs during 7 days [55].
However, these doses are very high compared to the doses
used in our study and are not representative for human
exposure.
Nemmar et al. has indicated the importance of cross-
talk between the pulmonary and systemic compartment
in a study where the neutrophil enzyme elastase, secretedby pulmonary neutrophils, was responsible for the periph-
eral thrombotic effect observed in a hamster model [56].
Neutrophil elastase has been shown to promote the fi-
brinogen binding activity of the platelet integrin αIIbβ3 by
cleaving the αIIb subunit. This cleavage potentiates plate-
let aggregation induced by low concentrations of cathepsin
G, another neutrophil protease [57,58].
Genotype-related effects
Along the NP-induced effects, there were also significant
differences in the blood parameters between both geno-
types. The Bmal1−/− mice exhibit higher amounts of
WBCs, RBCs and platelets, and showed a prothrombotic
phenotype as evidenced by shorter PT and increased
fibrinogen and coagulation FVII concentrations. These re-
sults confirm earlier reports [17,19]. Moreover, the corre-
lations between the pulmonary endpoints (inflammation
and oxidative stress) and hemostasis parameters were
more pronounced in the Bmal1−/− mice, than in the
Bmal1+/+ mice, suggesting that the Bmal1−/− are more
sensitive to nanomaterial-induced effects, confirming our
hypothesis.
A potential explanation for this prothrombotic pheno-
type is the deregulation of e.g. PAI-1, the most import-
ant regulator of fibrinolysis. PAI-1 is subject to diurnal
variation, but in the Bmal1−/− mice these levels are con-
tinuously elevated resulting in an imbalance between fi-
brinolysis and its inhibition [17]. On the contrary,
Hemmeryckx et al. observed decreased PAI-1 gene ex-
pression in subcutaneous and gonadal adipose tissue
[59]. Also vWF is regulated by the circadian transcrip-
tion complex and Bmal1−/− mice have increased vWF
plasma levels, contributing to the prothrombotic pheno-
type in these mice.
Time-related effects
We also observed several “time-effects”: the pulmonary
parameters decreased over time whereas the RBCs,
platelets and coagulation increased over time. The fact
that the measured pulmonary endpoints were decreased
at T2 compared to T1 is not surprising. The observed
inflammatory and (anti-)oxidative responses attenuated
over the 8 weeks after the last exposure which is indica-
tive of a healing process. The changes observed regard-
ing RBCs and platelets are quite similar compared to the
findings of Hemmeryckx et al., however our RBC levels
are higher and platelet levels are lower as compared to
theirs [19]. They also reported in Bmal1−/− mice a sig-
nificantly decreased PT with age, significantly increased
FVII and trends towards increased coagulation factor
VIII and fibrinogen concentrations. Our results were less
pronounced and not consistent in all experimental
groups. This can probably be explained by the fact that
our mice at T2 were 10 weeks younger than the mice
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the prothrombotic effects due to ageing could not yet be
detected.
Lately, a lot of research focused on the progression of
atherosclerosis following pulmonary NP exposure. The
first step in the process of atherosclerosis is endothelial
activation with an upregulation of adhesion molecules
followed by the recruitment of macrophages to the vas-
cular wall [60]. We therefore stained sections of the
aorta for macrophages (F4/80 antigen) to assess whether
the NPs used in this study could initiate this process of
early atherogenesis. At the time points measured, we
could not detect any differences in macrophage staining
between the different experimental groups. However,
Cao et al. observed increased plaque formation in ApoE−/−
mice (24 hours after the last instillation), using the same
MWCNTs and the same dose (25.6 μg/instillation) in the
same dosing scheme [12]. In the BMAL1−/− model, expos-
ure to MWCNT affected in a similar way the pulmonary
inflammation and oxidative stress: an increased neutro-
philic inflammation which was persistent up to 28 days
after the last administration, increased IL-1β, KC and 8-
isoprostane formation in the lung. The systemic effect ob-
served in the BMAL1−/− model differed significantly from
that in ApoE−/−, indicating that presumably the Bmal1−/−
mice are less prone to the development of atherosclerosis
compared to the dyslipidemic ApE−/− mice.
Conclusions
In a prothrombotic mouse model, Bmal1−/− mice, we
studied the pulmonary and hemostatic toxicity after a
subacute exposure to MWCNTs and ZnO NPs. The
MWCNTs induced a potent pulmonary inflammatory
response, induced hemolysis and were procoagulant,
shown by a reduced PT and increased fibrinogen con-
centrations. The ZnO NPs somewhat suppressed the
pulmonary inflammatory response but significantly in-
creased coagulation factor VIII. The procoagulant effects
and correlations between the pulmonary and hemostatic
endpoint were more pronounced in the Bmal1−/− mice
than the Bmal1+/+ mice. This study supports evidence
that the population with cardiovascular risk factors have
higher risks for the development of hemostatic toxicity
after pulmonary NP exposure. However, on the basis of
our data possibly also people with a disturbed circadian
rhythm, such as shift workers, could have a higher risk
of developing particle-related heart disease.
Methods
Animal model
Breeding couples of mice heterozygous for Bmal1 (100%
C57BL/6 J) were kindly provided by Dr K. Esser (Univer-
sity of Kentucky, Lexington, KY). Female Bmal1−/− mice
and Bmal1+/+ littermates were generated in the animalfacility of the KU Leuven and genotyped as described by
Bunger et al. [61].
All animals were kept in micro-isolation cages in a
temperature- and light-controlled (12-hour night/day cycle)
environment and had free access to drinking water and
standard chow ad libitum. All animal procedures were ap-
proved by the Ethical Committee for animal experiments
of the KU Leuven and performed in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals (1996).
Nanomaterials and preparation of exposure suspensions
The MWCNTs (Arkema Graphistrength C100; NM402)
and ZnO NPs were (BASF Z-Cote; zinkite, uncoated,
primary size: 100 nm, NM110) were obtained from the
European Commission Joint Research Centre Nano-
materials Repository (http://ihcp.jrc.ec.europa.eu/our_
activities/nanotechnology/nanomaterials-repository). De-
tailed physico-chemical characterization was performed
by Kermanizadeh et al. [62]. The X-ray diffraction (XRD)
size for the ZnO NPs ranged between 70 to >100 nm. As
determined by transmission electron microscopy (TEM),
the MWCNTs had a diameter of 6–20 nm and length of
700–4000 nm and the size of the ZnO NPs ranged be-
tween 20-250/50-350 nm. The Brunauer-Emmett-Teller
(BET) surface area was 225 and 14 m2/g for MWCNTs
and ZnO NPs respectively [62].
The dissolution of Zn + ions from the ZnO NP disper-
sions was determined within the framework of the
ENPRA (engineered nanoparticle risk assessment) pro-
ject. These measurements were performed at a slightly
different concentration (0.32 mg/ml) than the concen-
trations used in this study, namely 0.25 mg/ml (6.4 μg/
aspiration) and 0.51 mg/ml (12.8 μg/aspiration). At a
concentration of 0.32 mg/ml, the amount of Zn + ions
measured in DMEM medium (+10%FBS +1%PenStrep)
and water after 24 hours were 23.76 and 54.01 ppm re-
spectively. The estimated solubility limits were deter-
mined as 29.6 and 67.2 μg Zn/ml in medium and water
respectively [35]. In our experiments, dissolution of Zn
is expected to be higher than 20 μg/ml, in both dose
concentration, at the time of exposure. The dissolution
kinetics of ZnO in the lung has not been assessed.
The NPs were weighed and dispersed in sterile water
containing 2 vol% mouse serum (dispersion medium) to
create a stock concentration of 2.56 mg/ml. Mouse
serum was obtained from full blood from Bmal1+/− mice.
Blood, taken from the inferior vena cava, was collected
in Minicollect serum tubes, left at room temperature for
30 minutes and centrifuged at 2000 g for 10 minutes.
The serum was collected and tested to be free of LPS
(LAL assay).
The NP stock suspensions were sonicated using a
Microson™ ultrasonic cell disruptor (Misonix, Newtown,
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nutes on ice/water. Thereafter, the stock concentrations
were diluted to obtain the final concentrations for ex-
posure: 160 and 640 μg/ml MWCNT (corresponding to
6.4 and 25.6 μg/dosing) and 256 and 512 μg/ml ZnO
(corresponding to 6.4 and 12.8 μg/dosing). Based on pre-
liminary studies, we chose to lower the dose of ZnO
NPs exposure since the pulmonary administration of
25 μg ZnO NPs induced an acute mortality, whereas a
dose of 12.5 μg did not [63].
The NP suspensions were used within one hour after
sonication.Study design (Experimental lay-out)
Bmal1−/− and Bmal1+/+ mice were dosed (under light
anesthesia with isoflurane) via oropharyngeal aspiration
once a week, during 5 consecutive weeks. The first dose
was administered at the age of 8 weeks. For the MWCNT,
the Bmal1 mice were either dosed 6.4 μg per aspiration
(total amount administered of 32 μg) or 25.6 μg per aspir-
ation (total of 128 μg). For the ZnO NPs, mice were either
dosed 6.4 μg or 12.8 μg per aspiration (for a total of 32 μg
or 64 μg respectively). Each administration consisted of a
volume of 25 μl. The control animals received the disper-
sion medium. Mice were sacrificed either, 24 hours after
the last administration (T1, age of 12 weeks) or 8 weeks
after the last administration (T2, age of 20 weeks).
The mice were sacrificed using an intraperitoneal
overdose of pentobarbital. Blood was immediately taken
via the retro-orbital plexus and collected in a tube con-
taining citrate. The end concentration of citrate in the
blood was 0.38%. A broncho-alveolar lavage (BAL) was
performed, consisting of two flushes of 1 ml/25 g body
weight. The aortic arc/bow was taken and used for hist-
ology (kept at 4% formaldehyde). Finally, the lung-heart
block was taken and the superior lobe of the right lung
and the heart were kept on 4% formaldehyde for histology.
The left lung was snap-frozen for GSSG/GSH measure-
ments. The remaining lobes of the right lung were also
snap-frozen and kept for cytokine measurements.Blood samples
Immediately after the withdrawal, a small portion of the
blood was diluted 5-fold (in saline) to perform cell
counts using the Cell-Dyn® 3200 R counter (Abbott
Diagnostics, Louvain-la-Neuve, Belgium). The remaining
part of the blood was immediately centrifuged twice at
16100 g, for 10 minutes at room temperature. The
plasma was stored at −80°C for measurements of the
partial thromboplastin time (aPTT), the prothrombin
time (PT) and plasma levels of coagulation factors (F)
VII, FVIII and fibrinogen using the BCS-XP automated
coagulation analyzer (Siemens, Beerzel, Belgium).Broncho-alveolar lavage
The pooled BAL fluid was centrifuged at 400 g, for
10 minutes at 4°C. The supernatant was stored at −80°C.
The cell pellet was resuspended and a total cell count
was performed using a Bürker cell counter. Cells were
spun on microscope slides at 300 g for 6 minutes (Cytos-
pin 3, Shandon, TechGen, Zellik, Belgium) and stained
using the DiffQuick® method (Medical Diagnostics,
Düdingen, Germany). For each sample, the number of
macrophages, neutrophils, eosinophils and lymphocytes
were counted.
Cytokine release
The lung tissue was homogenized in 0.5 ml of 1% bovine
serum albumin (BSA in HBSS-) and afterwards centri-
fuged at 16100 g, 4°C for 10 minutes. The supernatant
was frozen at −80°C until cytokine measurement using
the MSD mouse pro-inflammatory 7-plex (IFN-γ, IL-1β,
IL-6, IL-10, IL-12p70, KC/GRO, TNF-α) according to
the manufacturer’s instructions (Meso Scale Discovery,
Gaithersburg, Maryland, USA).
Glutathione determination
The left lung was homogenized on ice in cold 40 mM N-
ethylmaleimide (20 ml/g tissue, to prevent rapid oxidation
of GSH) and then centrifuged at 14000 g for 15 minutes at
4°C. The supernatant was transferred to a new tube and
5% metaphosphoric acid was added (1/5th of the super-
natant volume, final concentration is 1% metaphosphoric
acid, for removing the proteins), mixed and again centri-
fuged at 14000 x g during 15 minutes at 4°C. The super-
natant was stored at −80°C until measurements. The
measurements of the reduced (GSH) and oxidized (gluta-
thione disulfide, GSSG) forms of glutathione were per-
formed by ultra-pressure liquid chromatography (UPLC),
in combination with tandem mass spectrometry (MS-
MS). An in-house developed LC/MS-MS method was
used, partially based on the method of Guan et al. as
follows. The LC/MS-MS analysis was conducted on a
Waters® Acquity TM UPLC coupled to a Waters® Micro-
mass MS Technologies Quattro Premier TM mass spec-
trometer using electro spray ionization (ESI). The LC
separation was done on a Waters Acquity UPLC BEH
C18, 50 mm × 2.1 mm, 1.7 μm column, held at a
temperature of 40°C. The mobile phase used for the LC
separation was a mixture of 0.1% formic acid in water and
0.1% formic acid in acetonitrile. The flow rate was
0.35 ml/min and the total run time was 4 minutes. Ten μl
aliquots were injected per sample. The analyses were per-
formed in the ESI +mode and a multiple reaction moni-
toring (MRM) methodology was used with argon as the
collision gas.
Data were normalized to protein content measured by
the Bradford method using bovine serum albumin as the
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Histology
The arc/bow of the aortic tissues was embedded in par-
affin, dehydrated in ethanol (70%-96%-100%) and cleared
in xylene. Sections (7 μm) were vertically cut (perpen-
dicular to the surface of the tissue) using a HM360
microtome (Microm, Walldorf, Germany). Subsequently,
they were deparaffinized in xylene, followed by decreas-
ing series of ethanol concentrations and distilled water.
The sections were stained for F4/80. To expose F4/80
antigens, the sections were treated with 10 mM Na3-
citrate with 0.05% Tween during 40 minutes at 95°C and
afterwards allowed to cool. The endogenous peroxidase
activity was blocked by incubating the sections in metha-
nol supplemented with 0.3% H2O2 during 20 minutes at
RT. Afterwards, the sections were incubated with TNB
during 45 minutes and then the rat anti-mouse antibody
(2 μg/ml, Serotec, Puchheim, Germany) was incubated
overnight. The slides were incubated with the second-
ary antibody (rabbit anti rat Ig-biotin, DAKO) during
45 minutes and afterwards the signal was amplified
using the biotinyl tyramide kit (1/50, NEL700001KT,
Perkin Elmer Life Sciences, Zaventem, Belgium). F4/80
signals were visualized with 3,3'-Diaminobenzidine (DAB,
Sigma-Aldrich, Diegem, Belgium).
Statistical analysis
The associations between each biological endpoint and
treatment groups were studied for MWCNT and ZnO
NPs separately. Data from one single control group were
used for comparison with both MWCNT and ZnO NP
administration. The experimental set-up with three
different variables (i.e. genotype; concentration of NP
administered: control, low, high; time of measurement
after administration) and all possible combinations
called for a three-way ANOVA model, allowing for
three-way interactions and pairwise two-way interactions
between the three explanatory variables. For each end-
point, we built a full model including main effects and
all two-way and three-way interaction terms. Then, non-
significant interaction terms or main effects (p > 0.05)
were manually removed from the model in a stepwise
procedure. Whenever interaction terms involving geno-
type showed statistical significance, subsequent subgroup
analyses were performed for Bmal1+/+ and Bmal1−/− mice
separately.
BAL cell type concentrations were highly positively
intercorrelated, and so were WBC types. Therefore, in
order to summarize all BAL cell or WBC types in one
model (meanwhile reducing the risk of making a type I
error), we performed a principal component analysis
(PCA) of BAL cell types and WBC types, respectively.The first component resulting from the PCA was inter-
preted as an overall indicator of BAL cells or WBC aug-
mentation and analyzed in a three-way ANOVA model
similar to the one-by-one analysis of BAL cell types and
WBC types.
Associations among specific biological endpoints were
further explored by Pearson’s correlation analyses; initially
for MWCNT and ZnO NP treatment separately and fi-
nally grouping the NP exposures per mouse phenotype.
Results are reported as the percentage of the control.
Statistical analyses were performed using SAS software,
version 9.3. (SAS Institute, Cary, NC, USA) and all tests
were two-sided with α = 0.05.
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